{"id":"NCT02709746","sponsor":"H. Lundbeck A/S","briefTitle":"Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)","officialTitle":"Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05","primaryCompletion":"2019-07-02","completion":"2019-07-30","firstPosted":"2016-03-16","resultsPosted":"2020-08-19","lastUpdate":"2020-08-19"},"enrollment":784,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Vortioxetine 10 mg/day","otherNames":["Brintellix ®","Lu AA21004"]},{"type":"DRUG","name":"Vortioxetine 20 mg/day","otherNames":["Brintellix ®","Lu AA21004"]},{"type":"DRUG","name":"Fluoxetine 20 mg/day","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vortioxetine 10 mg/day","type":"EXPERIMENTAL"},{"label":"Vortioxetine 20 mg/day","type":"EXPERIMENTAL"},{"label":"Fluoxetine 20 mg/day,","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).","primaryOutcome":{"measure":"Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment","timeFrame":"From Randomization to Week 8","effectByArm":[{"arm":"Vortioxetine 10 mg/Day","deltaMin":-17.09,"sd":1.27},{"arm":"Vortioxetine 20 mg/Day","deltaMin":-18.94,"sd":1.22},{"arm":"Fluoxetine 20 mg/Day,","deltaMin":-21.95,"sd":1.23},{"arm":"Placebo","deltaMin":-18.22,"sd":1.22},{"arm":"Vortioxetine Average (Avg. VOR)","deltaMin":-18.01,"sd":0.98}],"pValues":[{"comp":"OG000 vs OG003","p":"0.4702"},{"comp":"OG001 vs OG003","p":"0.6373"},{"comp":"OG002 vs OG003","p":"0.0152"},{"comp":"OG003 vs OG004","p":"0.8778"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":1},"locations":{"siteCount":124,"countries":["United States","Bulgaria","Canada","Colombia","Estonia","France","Germany","Hungary","Italy","Latvia","Mexico","Poland","Russia","Serbia","South Africa","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["35033635"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":777},"commonTop":["Headache","Nausea","Nasopharyngitis","Dizziness","Vomiting"]}}